Clinicians observed that the treatment of premature human newborns for anemia with erythropoietin (Epo) also improved their respiratory autonomy. This observation is in line with our previous in vitro studies showing that acute and chronic Epo stimulation enhances fictive breathing of brainstem-spinal cord preparations of postnatal day 3-4 mice during hypoxia. Furthermore, we recently reported that the antagonization of the cerebral Epo (by using the soluble Epo receptor; sEpoR) significantly reduced the basal ventilation and the hypoxic ventilatory response of 10 days old mice. In this study, we used transgenic (Tg21) mice to investigate the effect of the chronic cerebral Epo overexpression on the modulation of the normoxic and hypoxic ventilatory drive during the post-natal development. Ventilation was evaluated by whole body plethysmography at postnatal ages 3 (P3), 7 (P7), 15 (P15) and 21 (P21). In addition Epo quantification was performed by RIA and mRNA EpoR was evaluated by qRT-PCR. Our results showed that compared to control animals the chronic Epo overexpression stimulates the hypoxic (but not the normoxic) ventilation assessed asV E /V O 2 at the ages of P3 and P21. More interestingly, we observed that at P7 and P15 the chronic Epo stimulation of ventilation was attenuated by the down regulation of the Epo receptor in brainstem areas. We conclude that Epo, by stimulating ventilation in brainstem areas crucially helps tolerating physiological (e.g., high altitude) and/or pathological (e.g., respiratory disorders, prematurity, etc.) oxygen deprivation at postnatal ages.
Introduction
By activating erythropoiesis in bone marrow and augmenting the oxygen carrying capacity of the arterial blood, erythropoietin (Epo) is known as a central molecule regulating tissue oxygenation (Jelkmann, 2007) . However, apart from the peripheral erythropoietic system, our research demonstrated that Epo is also a crucial factor regulating the neural control of ventilation by interacting with the respiratory network located in the brainstem (Soliz et al., 2005) . In our last study we showed that the intracisternal administration of soluble Epo receptor (sEpoR, a competitive antagonist of Epo) in the brainstem of newborn and adult C57/Bl6 mice signifi- * Corresponding author.
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cantly decreases the minute ventilation and the hypoxic ventilatory response. Accordingly, we concluded that endogenous cerebral Epo is a potent respiratory stimulant (Ballot et al., 2015) . Furthermore, recent data obtained on the in vitro preparation of the isolated brainstem spinal cord of newborn mice showed that Epo reduces the classical hypoxic depression of the fictive breathing frequency (Khemiri et al., 2011) . Moreover, the hypoxic depression was blunted when using brainstem spinal cord preparations of transgenic (Tg21) mice constitutively overexpressing Epo in the brain (Caravagna et al., 2014; Caravagna and Soliz, 2015) . Considering that respiratory disorders in newborns (especially on those born prematurely) are major causes of morbidity, our findings are of clinical relevance. In fact, subcutaneous treatment of premature neonates (gestational age < 30 weeks) with Epo (300 U/kg/dose, 3 times/week) has been recently reported to improve both erythropoiesis (higher hemoglobin, hematocrit and reticulocytes) and ventilatory function (reduced need of assisted ventilation and O 2 supplementation) (Tempera et al., 2011) . Although a better hematological status may help to stabilize http://dx.doi.org/10.1016/j.ijdevneu.2015.06.001 0736-5748/© 2015 ISDN. Published by Elsevier Ltd. All rights reserved.
